BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 16842157)

  • 1. Hsp90: a novel target for cancer therapy.
    Solit DB; Rosen N
    Curr Top Med Chem; 2006; 6(11):1205-14. PubMed ID: 16842157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
    Stravopodis DJ; Margaritis LH; Voutsinas GE
    Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer.
    Haque A; Alam Q; Alam MZ; Azhar EI; Sait KH; Anfinan N; Mushtaq G; Kamal MA; Rasool M
    Curr Pharm Des; 2016; 22(20):2947-59. PubMed ID: 27013225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hsp90 molecular chaperone inhibitors: are we there yet?
    Neckers L; Workman P
    Clin Cancer Res; 2012 Jan; 18(1):64-76. PubMed ID: 22215907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents.
    Miyata Y
    Curr Pharm Des; 2005; 11(9):1131-8. PubMed ID: 15853661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HSP90 inhibitors: current development and potential in cancer therapy.
    Sidera K; Patsavoudi E
    Recent Pat Anticancer Drug Discov; 2014 Jan; 9(1):1-20. PubMed ID: 23312026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using natural product inhibitors to validate Hsp90 as a molecular target in cancer.
    Neckers L
    Curr Top Med Chem; 2006; 6(11):1163-71. PubMed ID: 16842153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
    Kim T; Keum G; Pae AN
    Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics - an update.
    Neckers L; Neckers K
    Expert Opin Emerg Drugs; 2005 Feb; 10(1):137-49. PubMed ID: 15757409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in Hsp90 inhibitors as antitumor agents.
    Messaoudi S; Peyrat JF; Brion JD; Alami M
    Anticancer Agents Med Chem; 2008 Oct; 8(7):761-82. PubMed ID: 18855578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HSP90 inhibitors: multi-targeted antitumor effects and novel combinatorial therapeutic approaches in cancer therapy.
    Hwang M; Moretti L; Lu B
    Curr Med Chem; 2009; 16(24):3081-92. PubMed ID: 19689285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent Advances in the Discovery of Novel HSP90 Inhibitors: An Update from 2014.
    Xiao Y; Liu Y
    Curr Drug Targets; 2020; 21(3):302-317. PubMed ID: 31465284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors.
    Zaarur N; Gabai VL; Porco JA; Calderwood S; Sherman MY
    Cancer Res; 2006 Feb; 66(3):1783-91. PubMed ID: 16452239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on Hsp90 inhibitors in clinical trial.
    Kim YS; Alarcon SV; Lee S; Lee MJ; Giaccone G; Neckers L; Trepel JB
    Curr Top Med Chem; 2009; 9(15):1479-92. PubMed ID: 19860730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibiting HSP90 to treat cancer: a strategy in evolution.
    Whitesell L; Santagata S; Lin NU
    Curr Mol Med; 2012 Nov; 12(9):1108-24. PubMed ID: 22804235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent updates on the development of ganetespib as a Hsp90 inhibitor.
    Choi HK; Lee K
    Arch Pharm Res; 2012 Nov; 35(11):1855-9. PubMed ID: 23212626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and development of purine-scaffold Hsp90 inhibitors.
    Chiosis G
    Curr Top Med Chem; 2006; 6(11):1183-91. PubMed ID: 16842155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting multiple signal transduction pathways through inhibition of Hsp90.
    Zhang H; Burrows F
    J Mol Med (Berl); 2004 Aug; 82(8):488-99. PubMed ID: 15168026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenomics in cancer drug discovery and development: inhibitors of the Hsp90 molecular chaperone.
    Workman P
    Cancer Detect Prev; 2002; 26(6):405-10. PubMed ID: 12507224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Purine-scaffold Hsp90 inhibitors.
    Chiosis G; Tao H
    IDrugs; 2006 Nov; 9(11):778-82. PubMed ID: 17096299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.